Bluebird bio to Spin Off its Oncology Business into Independent Company

Shots:

  • Bluebird plans to separate its severe genetic disease & oncology businesses into differentiated and independent publicly traded companies. The company will retain focus on SGD and will launch its oncology business (“Oncology Newco”) as a new entity
  • The spinoff is expected to result in two independent, publicly traded companies by the end of 2021
  • The spinoff is designed to unlock value through improved operational execution, organizational focus, tailored capital allocation, and enhanced strategic optionality

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Fierce Pharma

The post Bluebird bio to Spin Off its Oncology Business into Independent Company first appeared on PharmaShots.

Bausch Health to Spin off its Eye Health Business

Shots:

  • Bausch Health spin-off its leading eye health business into an independent publicly-traded company under the name Bausch + Lomb. The spinoff is expected to be completed in H1’21
  • The spinoff will lead to the formation of two separate companies that include an eye-health company built on the iconic Bausch + Lomb brand and a diversified company with leading positions in gastroenterology, aesthetics/dermatology, neurology, and international pharmaceuticals
  • Bausch + Lomb will consist of Bausch Health’s global vision care, surgical, consumer and ophthalmic Rx businesses which had generated $3.7B revenue in 2019. The other company would comprise brands across the Salix, International Rx, neurology and medical dermatology businesses that generated a revenue pf ~$4.9B in 2019

Click here ­to­ read full press release/ article | Ref: Bausch Health | Image: Pinterest